Gosset
Book a demo

ASCO Annual Meeting 2026: key results and trends

What the 7,281 abstracts at ASCO Annual Meeting 2026 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated, and how this edition compares with earlier years.

abstracts
7,281
10% more than 2025
drug-linked abstracts
2,794
companies
532
from Phase 3 studies
389

Drug-linked abstracts by phase

  • Phase 1 330
  • Phase 1/2 210
  • Phase 2 643
  • Phase 2/3 37
  • Phase 3 389
  • Phase 4 5

Key results

Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue

  1. Phase 3Aggressive fibromatosis (AF)Immunome

    varegacestat

    RINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors.

    VAR demonstrated significantly better PFS compared with PBO (hazard ratio [HR]: 0.16 [95% CI: 0.07, 0.38; P <0.0001]).

    Read the abstract (opens in a new tab)

  2. Phase 3Multiple myeloma (MM)

    teclistamab

    MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).

    With 17.3-mo median follow-up, Tec significantly improved PFS vs PVd/Kd (HR, 0.29; 95% CI, 0.23–0.38; P <0.0001); mPFS: NR vs 8.2 mo; 18-mo PFS rate: 69.8% vs 26.9%.

    Read the abstract (opens in a new tab)

  3. Phase 3Triple-negative breast cancer (TNBC)

    izalontamab brengitecan

    Izalontamab brengitecan (iza-bren) versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study.

    The confirmed objective response rate (cORR) assessed by BICR was 51.7% with iza-bren and 20.5% with TPC (odds ratio, 4.28 [95% CI, 2.75-6.66]).

    Read the abstract (opens in a new tab)

  4. Phase 3Breast cancerCelcuity

    gedatolisib

    A randomized, open-label, phase 3 study of gedatolisib + fulvestrant ± palbociclib vs standard of care in HR+/HER2−/ PIK3CA -mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2).

    Median PFS for the geda doublet (n=52) vs alpelisib/fulv was 11.3 vs. 5.6 mos (HR, 0.51; 95% CI, 0.33-0.79; P<0.0013).

    Read the abstract (opens in a new tab)

  5. Phase 3Chemotherapy-induced nausea and vomiting (CINV)

    rolapitant + palonosetron

    Randomized, double-blind phase 3 trial of the fixed-dose combination fosrolapitant/palonosetron (HR20013) plus dexamethasone for prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

    Time to treatment failure analysis favored HR20013 (HR 0.52, 95% CI 0.40–0.69).

    Read the abstract (opens in a new tab)

  6. Phase 3Gastrointestinal stromal tumor (GIST)Cogent Biosciences

    bezuclastinib

    Primary results of the phase 3 peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST).

    ORR significantly improved with the combination vs monotherapy (46% vs 26%; risk difference, 20%; 95% CI, 10.6-28.6; P<0.0001).

    Read the abstract (opens in a new tab)

  7. Phase 3Neurofibromatosis type 1 (NF1)Fosun Pharma

    luvometinib

    Luvometinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: A randomized, double-blind, placebo-controlled, phase 3 trial.

    The median DOR was 15.1 months (95% CI, 14.8-NE), with a 85.2% rate of DOR ≥12 months with luvometinib.

    Read the abstract (opens in a new tab)

  8. Phase 3Gastric cancer (GC)Henlius

    serplulimab

    Neoadjuvant/adjuvant serplulimab vs. placebo combined with chemotherapy for PD-L1–positive gastric cancer: A randomized, double-blind, multicenter phase 3 study.

    Pathological complete response rate was higher in the serplulimab group than in the placebo group (21.6% vs 6.4%; odds ratio 3.95).

    Read the abstract (opens in a new tab)

  9. Phase 3Non-small cell lung cancer (NSCLC)

    sacituzumab tirumotecan

    Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.

    PFS by BICR was significantly longer in the sac-TMT + P group than the P group (median, not reached vs 5.7 months; HR, 0.35; 95% CI, 0.26-0.47; p < 0.0001).

    Read the abstract (opens in a new tab)

  10. Phase 3Liposarcoma

    abemaciclib

    SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.

    Abemaciclib demonstrated a statistically significant improvement in PFS at 9.67m vs placebo at 1.52m (hazard ratio [HR] 0.39; 95% confidence interval [CI], 0.25–0.59; p < 0.001).

    Read the abstract (opens in a new tab)

  11. Phase 3Rectal cancer

    tislelizumab

    Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab versus conventional short-course preoperative chemoradiotherapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (mRCAT-III): A multicenter, randomized, open-label, phase 3 trial.

    In the ITT population, the experimental group demonstrated a significantly superior pCR rate compared to the Control group: 61.4% (47/77) vs 28.6% (22/77) (P < 0.001).

    Read the abstract (opens in a new tab)

  12. Phase 3Prostate cancer (PCa)Pfizer

    talazoparib

    TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations.

    Interim analysis of OS favored TALA + ENZA but has not reached statistical significance (74 deaths TALA + ENZA, 91 deaths PBO + ENZA; HR, 0.767; 95% CI, 0.564–1.044).

    Read the abstract (opens in a new tab)

Small molecules, the most frequent modality, accounted for 55% of drug-linked abstracts, up from 44% in 2025. Monoclonal antibodies accounted for 37% of drug-linked abstracts, up from 29% in 2025. Peptides (2%) were new to the top modalities compared with 2025.

What the abstracts covered

Share of the 2,794 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.

  • Antibody-drug conjugates11%301 drug-linked abstracts · level with 10% in 2025
  • Bispecific antibodies8%223 drug-linked abstracts · from 6% in 2025

Top targets

  1. PDCD144216%
  2. ERBB21556%
  3. CD2741546%
  4. EGFR1415%
  5. TUBB1054%
  6. VEGFR21044%
  7. CD3994%
  8. VEGFR4873%
  9. VEGFR-1612%
  10. TSNew602%

Top modalities

  1. Small molecules1,52655% from 44% in 2025
  2. Monoclonal antibodies1,02637% from 29% in 2025
  3. Antibody-drug conjugates30111%
  4. Bispecific antibodies2238% from 6% in 2025
  5. Cell therapies1104%
  6. Radiopharmaceuticals1034%
  7. Non-antibody therapeutic proteins953%
  8. PeptidesNew692%

Top diseases

  1. Non-small cell lung cancer (NSCLC)31511%
  2. Breast cancer30711%
  3. Colorectal cancer (CRC)1485%
  4. Melanoma1154%
  5. Prostate cancer (PCa)1074%
  6. Gastric cancer (GC)1044%
  7. Triple-negative breast cancer (TNBC)1014%
  8. Head and neck squamous cell carcinoma (HNSCC)953%
  9. Ovarian cancer953%
  10. Hepatocellular carcinoma (HCC)943%

Most active companies

  1. Merck2007%
  2. Bristol Myers Squibb1535%
  3. AstraZeneca1385%
  4. Pfizer1084%
  5. Genentech1064%
  6. Eli Lilly783%
  7. Novartis763%
  8. Daiichi Sankyo662%
  9. Amgen652%
  10. BeiGene582%

ASCO over the years

  1. 20267,281 abstracts · this edition
  2. 20256,599 abstracts

Explore every ASCO 2026 result in Gosset

All 2,794 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.

This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.

Get full accessExplore the results in Gosset

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call